Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 3 | 2021 | 101 | 1.110 |
Why?
|
| Phosphoric Diester Hydrolases | 2 | 2018 | 46 | 0.980 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 4 | 2018 | 15 | 0.910 |
Why?
|
| Thyroid Hormones | 1 | 2018 | 23 | 0.550 |
Why?
|
| Glucose Oxidase | 1 | 2017 | 6 | 0.530 |
Why?
|
| Brain Neoplasms | 2 | 2021 | 319 | 0.530 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 281 | 0.520 |
Why?
|
| Hydrogen Peroxide | 1 | 2017 | 121 | 0.510 |
Why?
|
| Carrier Proteins | 1 | 2018 | 315 | 0.490 |
Why?
|
| Membrane Proteins | 1 | 2018 | 333 | 0.470 |
Why?
|
| Antioxidants | 1 | 2017 | 264 | 0.460 |
Why?
|
| Oxidative Stress | 2 | 2018 | 819 | 0.420 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2015 | 117 | 0.420 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 158 | 0.410 |
Why?
|
| Alzheimer Disease | 1 | 2015 | 338 | 0.330 |
Why?
|
| Neoplasms | 3 | 2015 | 1334 | 0.320 |
Why?
|
| Cell Line, Tumor | 3 | 2018 | 1470 | 0.230 |
Why?
|
| Pyruvate Kinase | 1 | 2021 | 7 | 0.170 |
Why?
|
| Signal Transduction | 2 | 2018 | 1748 | 0.150 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2018 | 6 | 0.140 |
Why?
|
| Quinazolines | 1 | 2018 | 34 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 1232 | 0.140 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2017 | 64 | 0.130 |
Why?
|
| Cyclooxygenase 2 | 1 | 2017 | 49 | 0.130 |
Why?
|
| Catalase | 1 | 2017 | 72 | 0.130 |
Why?
|
| Glioma | 1 | 2018 | 83 | 0.130 |
Why?
|
| Superoxide Dismutase | 1 | 2017 | 122 | 0.130 |
Why?
|
| DNA Repair | 2 | 2014 | 197 | 0.120 |
Why?
|
| Glutathione | 1 | 2017 | 303 | 0.120 |
Why?
|
| Cell Survival | 1 | 2017 | 600 | 0.120 |
Why?
|
| Rats | 2 | 2018 | 3162 | 0.110 |
Why?
|
| Genes, Lethal | 1 | 2015 | 2 | 0.110 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2015 | 11 | 0.110 |
Why?
|
| Protein Interaction Mapping | 1 | 2015 | 38 | 0.110 |
Why?
|
| Animals | 4 | 2018 | 13526 | 0.110 |
Why?
|
| Gene Silencing | 1 | 2015 | 122 | 0.110 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 252 | 0.110 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2015 | 147 | 0.110 |
Why?
|
| Drug Design | 1 | 2014 | 121 | 0.100 |
Why?
|
| Neurodegenerative Diseases | 1 | 2014 | 81 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 138 | 0.100 |
Why?
|
| Brain | 1 | 2021 | 1350 | 0.090 |
Why?
|
| Humans | 7 | 2021 | 53230 | 0.090 |
Why?
|
| Mice | 1 | 2015 | 5982 | 0.050 |
Why?
|
| Glycolysis | 1 | 2021 | 76 | 0.040 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2018 | 16 | 0.040 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2018 | 18 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2018 | 352 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 421 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1367 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2014 | 28 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 181 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 333 | 0.020 |
Why?
|
| Apoptosis | 1 | 2018 | 1139 | 0.020 |
Why?
|
| DNA Damage | 1 | 2014 | 309 | 0.020 |
Why?
|